{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:25:42Z","timestamp":1791689142815,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204998\/Z\/16\/Z"],"award-info":[{"award-number":["204998\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:50:09Z","timestamp":1749844209000},"page":"276-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial"],"prefix":"10.1016","volume":"9","author":[{"given":"Martin J.","family":"Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur T.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolan","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijjan","family":"Khoubehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Klimowska-Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Nohpal de la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Staffurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Thippu Jayaprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dudderidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Hellawell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babbin","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azman","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Imseeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiful","family":"Miah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abd-Alazeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.05.010_b0005","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","article-title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","volume":"29","author":"Vale","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0010","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.05.010_b0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.05.010_b0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euo.2020.07.004","article-title":"Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials","volume":"3","author":"Connor","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","article-title":"Systemic and tumor-directed therapy for oligometastatic prostate cancer: the SOLAR phase 2 trial in de novo oligometastatic prostate cancer","volume":"86","author":"Nickols","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.010_b0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-022-01662-7","article-title":"Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer","volume":"39","author":"Reyes","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging\u2013reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.010_b0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/modpathol.2017.158","article-title":"Treatment effects in prostate cancer","volume":"31","author":"Evans","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euo.2025.05.010_b0050","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Rad Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0055","unstructured":"UK SABR Consortium. Stereotactic ablative body radiation therapy (SABR): a resource UK SABR consortium (v.6.1). UK SABR Consortium; 2019."},{"key":"10.1016\/j.euo.2025.05.010_b0060","unstructured":"Khoo V. Conventional care versus radioablation (stereotactic body radiotherapy) for extracranial oligometastases (CORE) NCT02759783. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02759783."},{"key":"10.1016\/j.euo.2025.05.010_b0065","unstructured":"NHS England Clinical Commissioning. External beam radiotherapy for patients presenting with hormone sensitive, low volume metastatic prostate cancer at the time of diagnosis [P200802P] (URN: 1901); 2020."},{"key":"10.1016\/j.euo.2025.05.010_b0070","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0090-4295(03)00351-0","article-title":"Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy","volume":"62","author":"K\u00f6llermann","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.05.010_b0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bju.15669","article-title":"Feasibility and safety of radical prostatectomy for oligometastatic prostate cancer: TRoMbone trial","volume":"130","author":"Sooriakumaran","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.05.010_b0080","unstructured":"ClinicalTrials.gov. Standard systemic therapy with or without definitive treatment in treating participants with metastatic prostate cancer (SWOG 1802). NCT03678025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03678025."},{"key":"10.1016\/j.euo.2025.05.010_b0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.euo.2024.06.010","article-title":"preferences for cytoreductive treatments in newly diagnosed metastatic prostate cancer: the IP5-MATTER study","volume":"8","author":"Connor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0090","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.05.010_b0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euo.2018.03.002","article-title":"Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases","volume":"1","author":"Heidenreich","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41571-019-0284-3","article-title":"Cytoreductive treatment strategies for de novo metastatic prostate cancer","volume":"17","author":"Connor","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0105","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0110","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1007\/s00261-020-02798-8","article-title":"The role of multiparametric resonance and biopsy in prostate cancer detection: comparison with definitive histological report after laparoscopic\/robotic radical prostatectomy","volume":"45","author":"Rapisarda","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.euo.2025.05.010_b0115","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.acra.2019.10.017","article-title":"Multiparametric MRI as a biomarker of response to neoadjuvant therapy for localized prostate cancer\u2014a pilot study","volume":"27","author":"Fennessy","year":"2020","journal-title":"Acad Radiol"},{"key":"10.1016\/j.euo.2025.05.010_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2012.02.029","article-title":"Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy","volume":"62","author":"Tewari","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.010_b0125","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.010_b0130","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eururo.2018.12.030","article-title":"Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry","volume":"76","author":"Shah","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.010_b0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41391-021-00335-2","article-title":"Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: A propensity score-based study","volume":"24","author":"Wang","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.05.010_b0140","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","article-title":"Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter European study","volume":"7","author":"Rajwa","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:36:40Z","timestamp":1778899000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931125001488"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}